225 related articles for article (PubMed ID: 34001842)
1. ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion.
Qin S; Ingle JN; Kim W; Gao H; Weinshilboum RM; Wang L
Pharmacogenet Genomics; 2021 Sep; 31(7):155-164. PubMed ID: 34001842
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
Qin S; Ingle JN; Liu M; Yu J; Wickerham DL; Kubo M; Weinshilboum RM; Wang L
Breast Cancer Res; 2017 Aug; 19(1):95. PubMed ID: 28821270
[TBL] [Abstract][Full Text] [Related]
3. 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
Wang G; Qin S; Zayas J; Ingle JN; Liu M; Weinshilboum RM; Shen K; Wang L
Breast Cancer Res Treat; 2019 Jun; 175(3):567-578. PubMed ID: 30937657
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
Ingle JN; Liu M; Wickerham DL; Schaid DJ; Wang L; Mushiroda T; Kubo M; Costantino JP; Vogel VG; Paik S; Goetz MP; Ames MM; Jenkins GD; Batzler A; Carlson EE; Flockhart DA; Wolmark N; Nakamura Y; Weinshilboum RM
Cancer Discov; 2013 Jul; 3(7):812-25. PubMed ID: 23764426
[TBL] [Abstract][Full Text] [Related]
5.
Ho MF; Ingle JN; Bongartz T; Kalari KR; Goss PE; Shepherd LE; Mushiroda T; Kubo M; Wang L; Weinshilboum RM
Mol Pharmacol; 2017 Aug; 92(2):175-184. PubMed ID: 28615284
[TBL] [Abstract][Full Text] [Related]
6. ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer.
Bond HM; Scicchitano S; Chiarella E; Amodio N; Lucchino V; Aloisio A; Montalcini Y; Mesuraca M; Morrone G
Front Endocrinol (Lausanne); 2018; 9():255. PubMed ID: 29867779
[TBL] [Abstract][Full Text] [Related]
7. SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.
Cairns J; Ingle JN; Wickerham LD; Weinshilboum R; Liu M; Wang L
PLoS Genet; 2017 Oct; 13(10):e1007031. PubMed ID: 28968398
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients.
Hato Y; Kondo N; Yoshimoto N; Endo Y; Asano T; Dong Y; Nishimoto M; Takahashi S; Fujii Y; Nakanishi R; Toyama T
Int J Clin Oncol; 2016 Jun; 21(3):539-47. PubMed ID: 26482374
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the
Liu D; Ho MF; Schaid DJ; Scherer SE; Kalari K; Liu M; Biernacka J; Yee V; Evans J; Carlson E; Goetz MP; Kubo M; Wickerham DL; Wang L; Ingle JN; Weinshilboum RM
NPJ Breast Cancer; 2017; 3():30. PubMed ID: 28856246
[TBL] [Abstract][Full Text] [Related]
10. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
11. AMPK Activation by Metformin Promotes Survival of Dormant ER
Hampsch RA; Wells JD; Traphagen NA; McCleery CF; Fields JL; Shee K; Dillon LM; Pooler DB; Lewis LD; Demidenko E; Huang YH; Marotti JD; Goen AE; Kinlaw WB; Miller TW
Clin Cancer Res; 2020 Jul; 26(14):3707-3719. PubMed ID: 32321715
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
13. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
14. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
15. A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer Metastasis.
Watters RJ; Verdelis K; Lucas PC; Jiang S; Chen Y; Lu F; Martin BM; Lukashova L; Pecar G; Morales-Restrepo A; Hankins M; Zhu L; Mittwede P; Hartmaier RJ; Alexander PG; Tseng GC; Weiss KR; Galson DL; Lee AV; Lee B; Oesterreich S
Endocrinology; 2021 Aug; 162(8):. PubMed ID: 33963375
[TBL] [Abstract][Full Text] [Related]
16. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
[TBL] [Abstract][Full Text] [Related]
17. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.
Fan C; Wang Y; Liu Z; Sun Y; Wang X; Wei G; Wei J
Int J Mol Med; 2015 Jul; 36(1):204-14. PubMed ID: 25999130
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.
Zou J; Hong L; Luo C; Li Z; Zhu Y; Huang T; Zhang Y; Yuan H; Hu Y; Wen T; Zhuang W; Cai B; Zhang X; Huang J; Cheng J
Cancer Sci; 2016 Dec; 107(12):1806-1817. PubMed ID: 27636742
[TBL] [Abstract][Full Text] [Related]
19. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
20. SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway.
Matsushima-Nishiwaki R; Yamada N; Hattori Y; Hosokawa Y; Tachi J; Hori T; Kozawa O
PLoS One; 2022; 17(1):e0262485. PubMed ID: 35007301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
